A macro-analysis of 49 different research papers (focusing primarily on animal studies) on the effects of CBD regarding multiple anxiety or stress-oriented disorders, such as Post-Traumatic Stress Disorder, Generalised Anxiety Disorder, and Social Anxiety Disorder to name a few.
Preclinical evidence demonstrates CBD’s efficacy in reducing anxiety behaviours relevant to multiple stress and anxiety based disorders. Early stage human experimental findings support these preclinical results, as well as demonstrating an excellent safety profile.
While more research needs to be carried out, the early stage findings seem promising with regards to using CBD as an anxiolytic agent.
Sativa Wellness Group (AQSE:SWEL) goal is to be recognised as one of the leading health companies, through building the best wellness brands in CBD testing services and products, to meet today’s fast evolving consumer expectations. Through full vertical integration of their supply chain and expansion of their distribution network, they plan to become one of the premier producers and high-quality distributors of CBD and wellness products and services in Europe.